uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.
Clinical role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
Images and patients
CT/CTA · Multi-region
Key limitation
Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyCT/CTA · Multi-region
Workflow roleCT acquisition, reconstruction, visualization, and release-specific examination planning.
Required inputX-ray projection data acquired under supported patient, protocol, contrast, and dose conditions.
Output and human actionCross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.
Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
The exact FDA document reports non-clinical testing, including bench tests and a reader study, for the uCT ATLAS Astound and uCT ATLAS. Bench tests showed CardioBoost and AIIR passed the basic general IQ test per IEC 61223-3-5. Readers rated AIIR and FBP images on a five-point scale; AIIR images were sufficient for diagnosis with quality equal or better than FBP, and CardioBoost images were sufficient for diagnosis with quality equal or better than KARL 3D. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical testing including bench test and reader study were conducted for the uCT ATLAS Astound with uWS-CT Dual Energy Analysis and uCT ATLAS with uWS-CT Dual Energy Analysis" … "CardioBoost passed the basic general IQ test which satisfied the requirement of IEC 61223-3-5.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical testing, including bench tests and a reader study, for the uCT ATLAS Astound and uCT ATLAS. Bench tests showed CardioBoost and AIIR passed the basic general IQ test per IEC 61223-3-5. Readers rated AIIR and FBP images on a five-point scale; AIIR images were sufficient for diagnosis with quality equal or better than FBP, and CardioBoost images were sufficient for diagnosis with quality equal or better than KARL 3D. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical testing including bench test and reader study were conducted for the uCT ATLAS Astound with uWS-CT Dual Energy Analysis and uCT ATLAS with uWS-CT Dual Energy Analysis" … "CardioBoost passed the basic general IQ test which satisfied the requirement of IEC 61223-3-5.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K243617 FDA performance package for uCT ATLAS Astound with uWS-CT-Dual Energy Analysis; uCT ATLAS with uWS-CT-Dual Energy Analysis
DesignManufacturer CT-system, reconstruction, dual-energy, dose, image-quality, and software verification and validation
PopulationAdult and pediatric whole-body, head, cardiac, vascular, dual-energy, and labeled lung-screening workflows
Scopeexact submission
Tested versionuCT ATLAS Astound/uCT ATLAS with uWS-CT Dual Energy Analysis
IndependenceSponsor or vendor study
K243617
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
1 exact-submission FDA recall record in the 2026-09-02 openFDA snapshot identify K243617. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-0221-2026 is Open, Classified for Shanghai United Imaging Healthcare Co., Ltd. Computed Tomography X-ray System, Model:uCT ATLAS MD, Rx Only. FDA reason: Third-party outer covers can become trapped between patient table and gantry, causing mechanical interference during table movement. FDA action: On September 12, 2025, UIH Technologies LLC, issued a recall notification to affected consignees. UIH asked consignees to take the following actions: 1. Ensure patient positioning clearance: When positioning the patient, confirm that arms and legs and clear of all table gaps and moving parts. 2. Avoid use of third-party slickers: We advise against the use of any non-UIH-approved slickers. 3. Service Contact: For technical assistance, contact your United Imaging Service engineer or reach out to our 24/7 Customer Contact Center, Toll-Free: (855) 221-1552/Direct: (832) 699-2799 4.Report adverse events: if any adverse events or quality issue occur, please report them to the FDA via the MedWatch program. 5. Please share this information with all relevant personnel at your facility, including technologist, service staff, and clinical teams.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: X-ray projection data acquired under supported patient, protocol, contrast, and dose conditions.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
Scope: Product family. Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Installed CT scanner hardware, console software, reconstruction options, and supported accessories.
Scope: Product family. Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Only qualified ct technologists and trained interpreting or treating physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K243617; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream-compatibility acceptance remains required.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
12Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
TrueFidelity deep-learning CT reconstruction produces selectable-strength images for supported head, whole-body, cardiac, and vascular applications on the Discovery CT750 HD family.
Philips Incisive CT provides head, whole-body, cardiac, and vascular CT imaging for patients of all ages and can support qualified low-dose lung screening under labeled programs and protocols.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.